Communiqués de presse Archive - Page 22 of 24 - Ose Immunotherapeutics - Société de biotechnologie intégrée qui développe des immunothérapies innovantes

OSE Immunotherapeutics Receives New European Patent Protection Through 2037 for OSE-703

OSE Immunotherapeutics Receives a Grant from the French National Research Agency

First Publication from OSE Immunotherapeutics on the Role of SIRPα in the Induction and Maintenance of Immune Tolerance

OSE Immunotherapeutics Receives Special Recognition for European Growth

OSE Immunotherapeutics Announces Results of 2019 Annual Shareholder Meeting

OSE Immunotherapeutics will participate in HealthTech Investor Days

Continuation of “Atalante 1” Phase 3 Clinical Trial of Tedopi® in NSCLC

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis

OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum

Précédent
1
…
19
20
21
22
23
24
Suivant